Vertical: HealthcareBase Year: 201814 Sections
Market Size (2018)
$346.75M
Projected (2025)
$8.72B
CAGR (2017–2025)
121.4%
Key Players
10+
Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells. The growing product development for the treatment of cancer by several companies is anticipated to fuel market growth. Additionally, the increase in clinical studies in this field, along with the rise in technological advancements globally is expected to support the growth of the market in the coming years.
The global CAR-T cell therapy market was valued at USD 346.75 million in 2018, and the market is estimated to grow at USD 8,716.06 million by 2025. In 2018, the US accounted for the largest market share of 86.63% with a market value of USD 300.39 million, followed by Europe with a market value of USD 31.75 million in 2018.
The global CAR-T cell therapy market has been segmented based on target antigen, application, and region/country.
Based on target antigen, the CD19 segment accounted for the largest market share of 98.79% in 2018, with a market value of USD 297.09 million, which is projected to register a CAGR of 59.20% during the forecast period.
Based on application, the diffuse large B-Cell lymphoma segment accounted for the largest market share of 84.61% in 2018, with a market value of USD 254.36 million, which is projected to register a CAGR of 57.29% during the assessment period.
The CART Cell Therapy Market market is projected to grow at a CAGR of 121.4% from 2017 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCAR-T cell therapy is a type of targeted therapy in which a patient’s T cells (T lymphocytes of the immune system) are engineered in a laboratory to treat cancer. In this process, the gene of the receptor for antigen, which is to be targeted during the treatment, is incorporated in the T-cell. This special receptor is called chimeric antigen receptor (CAR). Multiple copies of CAR cells are grown in the laboratory and infused in the patient’s body for treating cancer.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2017 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2017–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global CAR T cell therapy market is profitable both for existing players as well as new entrants. An intense rivalry is observed among the existing manufacturers in the market. According to the Wantstats analysis, it has been revealed that market players have adopted different strategies and innovations through active R&D to expand their business and secure their position in the global CAR T cell therapy market. An increasing number of clinical trial studies and the growing incidence of cancer are key factors that determine the market growth. In recent years, strategies adopted by major players included product launches, acquisitions, and approvals, which have been used for market penetration and to reduce competition. The major players in the global CAR T cell therapy market are Kite Pharma (Gilead Sciences, Inc.), Novartis AG, and Pfizer, Inc.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on geographic expansion and product improvement instead of just focusing on the development of novel offerings. International players are likely to strengthen their presence worldwide during the forecast period through acquisitions and regulatory approvals. It has also been predicted that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations can fuel the market growth, making it an ideal time to launch products and increase the global market share.
Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop technologies to stay abreast of emerging technologies that could affect the continuing competitiveness of their product lines in the market.
Threat of New Entrants
The threat of new entrants is high in the global CAR T cell therapy market. Any player trying to enter the market is required to comply with the mandatory regulatory standards. Moreover, the research and development of products are capital intensive and, in order to remain competitive, market players need to introduce innovative products for various therapeutic applications, which requires significant investments as well as time. However, the presence of lucrative growth opportunities in the market has increased the threat of new entrants.
Bargaining Power of Suppliers
The suppliers in the global CAR T cell therapy market are raw material manufacturers. There are various suppliers present in the global CAR T cell therapy market. The switching costs are low due to intense competition, and suppliers are likely to enter into long-term partnerships with CAR T cell therapy product manufacturers. The increasing research and development related to cell therapy and gene therapy has led to the entry of major pharmaceutical companies in the market.
However, the quality of raw materials plays an important role as the CAR T cell therapy products are used in the manufacturing of various cancer-curing drugs. Low-quality raw materials are likely to damage the quality of the final product. Hence, market players are selective about suppliers. Due to these factors, the bargaining power of suppliers in the global CAR T cell therapy market is moderate.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global CAR T cell therapy market. The market has a limited number of buyers and there are only a few CAR T cell therapy companies that to cater to the needs of these biotechnology and pharmaceutical companies. However, the CAR T cell therapy products are specialized, and the buyers are moderately inclined toward quality products manufactured by trusted companies; hence, they are likely to enter into long-term agreements with CAR T cell therapy product manufacturers for uninterrupted supply. They can also exert pressure on the manufacturers due to moderate switching costs and intense rivalry in the market. Currently, there are limited FDA-approved CAR T cell therapy products available in the market; however, there are several products in clinical trials, which are expected to be commercialized during the forecast period.
Threat of Substitutes
The threat of substitutes in the global CAR T cell therapy market is low to moderate. There are limited options available in the market to serve the need of the buyers. However, increasing research and development and the rising demand for safer CAR T cell therapy products are likely to result in the introduction of substitutes during the forecast period. Thus, the threat of substitutes in the global CAR T cell therapy market is low to moderate.
Intensity of Rivalry
The rivalry in the global CAR T cell therapy market is moderate to high. The low degree of product differentiation and a limited number of buyers increase the intensity of rivalry in the market. The market is growing and is projected to register a high growth rate during the review period, which offers opportunities to the key players to expand their geographic presence and increase market share, especially in emerging markets. This, along with a focus on the end-to-end development of products, helps market players reduce manufacturing and logistics costs, thereby increasing profitability and maintaining a high level of competition.
Market estimates by geography (2025)
InsightNorth America leads with $7.81B by 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2017 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $12.73M | $1.22B | $7.81B | 123.1% | 90% |
| Asia Pacific | $0.77M | $41.58M | $253.62M | 106.4% | 3% |
| Europe | $1.38M | $109.87M | $577.04M | 112.7% | 7% |
| Rest of the World | $0.20M | $14.02M | $80.13M | 111.5% | 1% |
| Total | $15.08M | $1.39B | $8.72B | 121.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$8.72B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| CD19 | $8.68B | 124.1% | 98% |
| CD22 | $182.07M | 75.3% | 2% |
| Others | $28.68M | 66.0% | 0% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on CART Cell Therapy Market covering market dynamics, competitive landscape, and strategic outlook.
The CART Cell Therapy Market market is projected to reach $8.72B by 2025, growing at 121.4% CAGR. The CD19 segment holds the largest share.
Cancer is a type of chronic disease. There are various treatment methods available for the treatment of cancer such as radiation therapy and chemotherapy, which kill both cancer as well as healthy cells. CAR T-cell therapy is an immune therapy that only targets cancer cells and reduces the risk of damage to healthy cells. Chimeric antigen receptor (CAR T), an autologous cell therapy, is one of the most effective treatment methods developed for the treatment of various cancer diseases. It is a type of immune cell treatment used for cancer patients. In this therapy, patient's T cells are isolated from patient’s blood and are inserted with chimeric antigen receptor (CAR) gene. Many CAR T-cells are grown in the laboratory, and these cells are infused to the patient’s body to kill the cancerous cell.
The key factors expected to drive the market growth are increasing prevalence of various types of cancers, technological advancements, growth of the pharmaceutical industry, and rise in the number of clinical studies for cell therapy.
However, the side effects pertaining to CAR T-cell therapy and the high cost of treatment are factors likely to hamper the global market growth during the review period.
The prevalence of cancers is increasing the demand for effective treatment. The number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018.
Excessive smoking and consumption of alcohol and tobacco are factors increasing the prevalence of cancer across the world. Additionally, obesity is also one of the reasons which may increase the prevalence of cancers. The growth of the obese population is further is expected to increase the demand for CAR T-cell therapy.
According to the World Health Organization (WHO) 2018 fact sheet, excessive consumption of tobacco results in 7 million deaths every year. Lung cancer is the leading cause of deaths across the globe, i.e., 37%.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the CART Cell Therapy Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Company Headquarters: Massachusetts, US Founded: 2015 Workforce: ~370+ Company Working: Mustang Bio is a subsidiary of Fortress Biotech, Inc. It is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s immune system to eliminate cancer cells. Mustang Bio aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (COH) and Fred Hutchinson Cancer Research Center in the development of proprietary CAR T therapies for many cancers. Mustang Bio’s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia
Company Headquarters: New Jersey, US Founded: 2014 Workforce: ~500 Company Working: Legend Biotech is a multinational biopharmaceutical company. The company has three core cell therapy platforms—CAR-T) T-cell receptor T-cell therapy (TCR-T), and allogeneic cell therapy. The company has been developing a strong pipeline of CAR-T products to treat solid and liquid tumors. Legend Biotech is utilizing the extensive cell therapy experience of its leaders and R & D staff, global clinical partners, and expanding research facilities. It is doing so to utilize the potential of cell therapy to treat diseases that are thought to be incurable, such as hematologic malignancies, solid tumors, infectious diseases, and autoimmune diseases
Company Headquarters: Washington, US Founded: 2013 Workforce: ~500 (2016) Company Working: Juno Therapeutics is a part of Celgene Corporation. It is a biopharmaceutical company formed through the collaboration of Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company is into the development of cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno Therapeutics is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. The company has its offices in the US and Germany. The company has its manufacturing plant in Washington, US.
Company Headquarters: France, Paris Founded: 1999 Workforce: ~161 Company Working: Cellectis is a clinical stage biotechnological company involved in the development of immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company operates through two segments—Therapeutics and Plants. Cellectis is currently developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL), UCART22 to treat ALL and non-Hodgkin lymphoma (NHL), ALLO-501 for treating relapsed/refractory NHL, and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm, among others
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Company Headquarter: California, US Founded: 1989 Workforce: ~200 Company Working: Sorrento Therapeutics (Sorrento) is an antibody-centric, clinical stage biopharmaceutical company that develops new treatments for cancer, inflammation, and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar antibodies, as well as clinical CAR-T therapies targeting solid tumors. It has a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB), clinical stage CAR-T, intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir).
10 interactive charts drawn from the CART Cell Therapy Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global CART Cell Therapy Market Rest Of The World Of Rest Of The World
Global CART Cell Therapy Market Europe and Europe Of Europe By Region
Global CART Cell Therapy Market China Of Asia Pacific
Global CART Cell Therapy Market United States Of North America
Global CART Cell Therapy Market By Region
CART Cell Therapy Market Rest Of The World
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
